NCT04687878 is a Phase 2 clinical trial of Insulin in Parkinson Disease, sponsored by dr.dargahi.

Who is sponsoring NCT04687878?

NCT04687878 is sponsored by dr.dargahi.

What drugs are being tested in NCT04687878?

Interventions in NCT04687878: Insulin, Normal saline.

What condition does NCT04687878 study?

NCT04687878 studies Parkinson Disease.

Is NCT04687878 still recruiting?

NCT04687878 is currently completed. Last updated 23 April 2024.

Last reviewed 2024-04-23 · How we verify

NCT04687878

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients

Completed Phase 2 Last updated 23 April 2024

What this trial tests

Phase 2 trial testing Insulin in Parkinson Disease in 28 participants. Completed in 20 September 2023.

Timeline

1 January 2020

Primary endpoint
20 June 2022

20 September 2023

Quick facts

Lead sponsor	dr.dargahi
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	28
Start date	1 January 2020
Primary completion	20 June 2022
Estimated completion	20 September 2023
Sites	1 location across Iran

Drugs / interventions tested

Insulin (insulin) — full drug profile →
Normal saline

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

dr.dargahi

Who can join

17 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the effect of intranasal insulin on motor and non-motor symptoms of patients with Parkinson's disease over a 12-week period.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
McFarthing K, Rafaloff G, Baptista MAS, Wyse RK, et al · · 2021 · cited 46× · PMID 34151864 · DOI 10.3233/jpd-219006
Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches.
Degirmenci Y, Angelopoulou E, Georgakopoulou VE, Bougea A. · · 2023 · cited 32× · PMID 37893474 · DOI 10.3390/medicina59101756
Nose-to-brain drug delivery: from bench to bedside.
Drath I, Richter F, Feja M. · · 2025 · cited 23× · PMID 40390100 · DOI 10.1186/s40035-025-00481-w
The Nasal-Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases.
Qiu Y, Huang S, Peng L, Yang L, et al · · 2025 · cited 18× · PMID 40487748 · DOI 10.1002/mco2.70213
FOXO family and neurodegenerative diseases: Mechanisms of action and therapeutic potential.
Lv Z, Liu X, Zhou Z, Huang Q, et al · · 2026 · PMID 42202637 · DOI 10.1016/j.redox.2026.104218

Verify or expand the search:

Other trials of Insulin

Trials testing the same drug.

NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
NCT07259564 — A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) · Phase 2 · not yet recruiting
NCT06762314 — Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes · Phase 2 · recruiting
NCT06781775 — GDM: Insulin with or Without Metformin? · Phase 4 · recruiting
NCT06391853 — Investigating Brain Insulin Resistance in Alzheimer Disease with IntraNasal Insulin : a Multimodal Neuroimaging Study · NA · withdrawn

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04687878 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by dr.dargahi
Last refreshed: 23 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04687878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing